Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 3/2023

01-09-2023 | Epstein-Barr Virus | editorial

Head and neck cancer revisited

Author: Assoc. Prof. PD Dr. Thorsten Füreder

Published in: memo - Magazine of European Medical Oncology | Issue 3/2023

Login to get access

Excerpt

Head and neck cancer (HNC) is a heterogenous disease involving multiple anatomical subsites such as the oral cavity, pharynx, and larynx. While incidence rates have been increasing during the last few decades, HNC remains the seventh most common cancer resulting in approximately 325,000 annual deaths globally [1]. Well-recognized risk factors for the development of HNC include alcohol consumption, smoking tobacco products, betel nut chewing, human papilloma virus (HPV), and Epstein–Barr virus (EBV) infections. …
Literature
1.
Gormley M, Creaney G, Schache A, et al. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233(9):780–6.CrossRefPubMedPubMedCentral
2.
Lechner M, Liu J, Masterson L, et al. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022;19(5):306–27.CrossRefPubMedPubMedCentral
3.
Leemans CR, Tiwari R, Nauta JJ, et al. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 1994;73(1):187–90.CrossRefPubMed
4.
Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol. 1995;104(12):946–54.CrossRefPubMed
5.
Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450–62.CrossRefPubMed
6.
Tao Y, Biau J, Sun XS, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol. 2023;34(1):101–10.CrossRefPubMed
7.
Machiels JP, Tao Y, Burtness B, et al. LBA5 primary results of the phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2022;33:S1399.CrossRef
8.
Resl C, Georg P, Döller C. New developments in radiation oncology for head and neck cancers. memo. 2023;16(3).
9.
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.CrossRefPubMed
10.
11.
Yu H, Yin X, Mao Y, et al. The global burden of nasopharyngeal carcinoma from 2009 to 2019: an observational study based on the global burden of disease study 2019. Eur Arch Otorhinolaryngol. 2022;279(3):1519–33.CrossRefPubMed
12.
Metadata
Title
Head and neck cancer revisited
Author
Assoc. Prof. PD Dr. Thorsten Füreder
Publication date
01-09-2023
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00907-z

Other articles of this Issue 3/2023

memo - Magazine of European Medical Oncology 3/2023 Go to the issue

short review

Late complications after oncological therapy

short review

New developments in radiation oncology for head and neck cancers

short review

Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer

short review

Current systemic treatment options and new developments in palliative first-line treatment of head and neck squamous cell carcinoma

leading article

Emerging molecular drugs for the treatment of gastroesophageal tumors

short review

Nasopharyngeal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits